Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral arteryocclusion
Autore:
Liu, XF; Fawcett, JR; Thorne, RG; Frey, WH;
Indirizzi:
Reg Hosp, Dept Neurol, Alzheimers Res Ctr, Stroke Lab, St Paul, MN 55101 USA Reg Hosp St Paul MN USA 55101 Res Ctr, Stroke Lab, St Paul, MN 55101 USA Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA Univ MinnesotaMinneapolis MN USA 55455 maceut, Minneapolis, MN 55455 USA
Titolo Testata:
NEUROSCIENCE LETTERS
fascicolo: 2, volume: 308, anno: 2001,
pagine: 91 - 94
SICI:
0304-3940(20010803)308:2<91:NIIGFR>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
BRAIN-DAMAGE; NEURONS; STROKE; INJURY; MODEL; IGF-1;
Keywords:
cerebral ischemia, focal; middle cerebral artery occlusion; neurological deficits; insulin-like growth factor-I; neuroprotection; intranasal delivery;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Liu, XF Reg Hosp, Dept Neurol, Alzheimers Res Ctr, Stroke Lab, St Paul, MN55101 USA Reg Hosp St Paul MN USA 55101 , Stroke Lab, St Paul, MN 55101 USA
Citazione:
X.F. Liu et al., "Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral arteryocclusion", NEUROSCI L, 308(2), 2001, pp. 91-94

Abstract

Insulin-like growth factor-I (IGF-I) has been proposed as a treatment for stroke. However, it does not efficiently cross the blood-brain barrier (BBB). Intracerebroventricular injection of IGF-I has been shown to offer protection against cerebral ischemic damage in rats although this invasive method of administration may not be practical in humans, Non-invasive intranasal(IN) delivery of IGF-I to the brain is a promising alternative. We have assessed the therapeutic effect of IN IGF-I in rats following middle cerebralartery occlusion (MCAO). Treatment was initiated 10 min after the onset ofMCAO and then again 24 and 48 h later. Intranasal dosing of 75 mug IGF-I (225 mug total IGF-I over 48 h) significantly reduced corrected infarct volumes by 60% vs. control (P < 0.01) and hemispheric swelling by 45.6% vs. control (P < 0.05). Neurologic function, assessed by the postural reflex, flexor response and adhesive tape tests, was also improved by IN IGF-I as compared to control. Our study indicates IN delivery of IGF-I holds significant promise as a non-invasive and efficacious method of bypassing the BBB for the treatment of stroke. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 17:44:31